|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08037 CH BIOTECH SER
Nominal 
0.000 (0.000%) | 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Turnover | 38,872 | 19.794% | 70,509 | 211,985 | 1,851,532 | 623,761 |
| Cost of Sales | (36,330) | 2.177% | (75,449) | (177,661) | (750,575) | (265,741) |
| Gross Profit | 2,542 | -- | (4,940) | 34,324 | 1,100,957 | 358,020 |
| 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | (52,713) | (16,186) | -- | -- | |
| Change in FV & Impairment on Others | (5,315) | -- | (40,798) | 9,795 | 19,091 | (31) | |
| Profit / (Loss) on Disposal | -- | -- | -- | (2) | 1,696 | -- | |
| Other Non-operating Items | -- | -- | -- | (26) | (3,707) | (2,687) | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | (7,678) | (4,180) | 0 | |
| Profit / (Loss) before Taxation | (37,159) | -70.569% | (252,797) | (142,025) | 862,826 | 180,668 | |
| Taxation | 406 | -22.960% | 943 | 1,319 | (157,258) | (48,096) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 4,747 | -89.639% | 53,708 | 45,259 | (447,481) | (113,187) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (32,006) | -59.951% | (198,146) | (95,447) | 258,087 | 19,385 | |
| 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Net Finance Costs / (Income) | 12,525 | 195.053% | 16,458 | 1,569 | 3,342 | 6,531 |
| Depreciation & Amortisation | 7,317 | -43.297% | 21,416 | 55,580 | 66,401 | 68,112 |
| Directors' Emoluments | -- | -- | 6,522 | 9,250 | 15,401 | 11,624 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Disclaimer | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -3.300 | -60.241% | -20.500 | -9.900 | 26.800 | 2.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 1.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | 3.731% | -- |
| Cash flow per share ($) | -- | -- | (0.157) | 0.199 | 0.501 | 0.042 |
| NBV per share ($) | 0.245 | -- | 0.272 | 0.480 | 0.626 | 0.410 |
| Remarks: | Real time quote last updated: 30/10/2025 07:39 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD -32,006 |
| %Change | -59.951% |
| EPS / (LPS) | HKD -0.033 |
| NBV Per Share ($) | HKD 0.245 |